Company news
China Meheco Group Co., Ltd. Class A (SSE:600056) news
China Meheco Group Co., Ltd. Class A news releases on 6ix. Latest, Sep 9, 2026: "China Meheco Group Co., Ltd."Announcement on Progress of Litigation Involving…
Press releases & updates
"China Meheco Group Co., Ltd."Announcement on Progress of Litigation Involving the Company
September 8, 2026
"China Meheco Group Co., Ltd."Announcement on Appointment of Board Secretary
September 7, 2026
"China Meheco Group Co., Ltd."Announcement on Departure of the Board Secretary
September 1, 2026
"China Meheco Group Co., Ltd."Announcement on Convening the 2026 Semi-annual Performance Briefing
August 25, 2026
"China Meheco Group Co., Ltd."Announcement on Completion of Redemption of the 1st Tranche of Super Short-term Commercial Papers for 2025
August 10, 2026
"China Meheco Group Co., Ltd."Announcement on Issuance Results of Super Short-term Commercial Paper for 2026
August 6, 2026
"China Meheco Group Co., Ltd."Announcement on the Proposed Selection of the Subsidiaries in the 12th Batch of National Centralized Drug Procurement
August 3, 2026
"China Meheco Group Co., Ltd."Announcement on Resolutions of the 5th Meeting of the 10th Board of Directors
July 28, 2026
"China Meheco Group Co., Ltd."Announcement on Obtaining Notice of Approval for Drug Supplementary Application
July 20, 2026
"China Meheco Group Co., Ltd."Announcement on the Subsidiary's Receipt of the Approval for Marketing of a Chemical API
July 16, 2026
Announcement on Implementation of Dividend Distribution for 2025
June 17, 2026
Announcement on Subsidiary Obtaining Approval for Marketing of Chemical APIs
June 8, 2026
Announcement on Subsidiary Obtaining Notice of Approval for Drug Supplementary Application
May 29, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
May 20, 2026
Report for Q1 2026
April 28, 2026
Announcement on 2025 Annual Profit Distribution Plan
April 24, 2026
Announcement on Obtaining Drug Registration Certificate by Subsidiary
April 20, 2026
Announcement on Result of Public Issuance of Corporate Bonds (Phase I) to Professional Investors in 2026
April 17, 2026
Announcement on Resolutions of the 2nd Meeting of the 10th Board of Directors
March 31, 2026
Announcement on Providing Guarantee for Holding Company
February 27, 2026
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
February 9, 2026
Announcement on Progress in Litigation Involved by the Company
February 5, 2026
Announcement on Obtaining Notice of Approval for Drug Supplementary Application
January 29, 2026
Notice on Convening the 1st Extraordinary General Meeting in 2026
January 23, 2026
Announcement on Reply to the Regulatory Work Letter Regarding Matters Related to Asset Acquisition
January 21, 2026
Announcement on Subsidiary's Drug Passing Generic Drug Consistency Evaluation
January 16, 2026
Announcement on Obtaining Registration Approval for Public Issuance of Corporate Bonds to Professional Investors
January 12, 2026
Announcement Regarding the Subsidiary's Receipt of the "Tax Matters Notice" and Related Matters Concerning the Payment of Back Taxes
December 31, 2025
Announcement on Resolutions of the 34th Meeting of the 9th Board of Directors
December 30, 2025
Announcement on Obtaining Drug Registration Approval by Subsidiary
December 24, 2025
Announcement on Resolutions of the 33rd Meeting of the 9th Board of Directors
November 24, 2025
Announcement on Results of Issuing Phase I Ultra-Short-Term Financing Bonds of 2025
November 12, 2025
Announcement on Convening the Q3 2025 Performance Briefing
November 4, 2025
Announcement on Prospective Winning of the Subsidiary in the 11th National Centralized Drug Procurement
October 28, 2025
Full Text of Report for Q3 2025
October 27, 2025
Announcement on Receipt of the "Notice of Registration Acceptance" from the National Association of Financial Market Institutional Investors
October 10, 2025
Announcement on Providing Guarantee for Wholly-owned Subsidiaries
September 19, 2025
Announcement on Convening the 2025 Semi-annual Performance Briefing
September 3, 2025
Announcement on Resolutions of the 31st Meeting of the 9th Board of Directors
August 27, 2025
Announcement on Subsidiary's APIs Obtaining CEP Certificate
August 13, 2025
Announcement on Resolutions of the 14th Meeting of the 9th Board of Supervisors
August 8, 2025
Notice on Convening the 5th Extraordinary General Meeting in 2025
July 23, 2025
Announcement on Resignation of Directors and General Managers
July 17, 2025
Announcement on Resolutions of the 4th Extraordinary General Meeting in 2025
July 11, 2025
Announcement on Implementation of Final Dividend Distribution for 2024
July 2, 2025
Announcement on Subsidiary Obtaining Notice of Approval for Drug Supplement Application
June 27, 2025
Announcement on Waiver of Preemptive Right for 24% Equity of Joint-stock Companies
June 24, 2025
Announcement on Resolution of the 3rd Extraordinary General Meeting in 2025
June 23, 2025
Announcement on Resolution of the 2nd Extraordinary General Meeting in 2025
May 28, 2025
Announcement on Reply to Letter of Regulation Regarding the Acquisition of Related Parties' Assets
May 26, 2025